Eli Lilly Requests Emergency Use Authorization for COVID-19 Treatment Candidate
Eli Lilly (NYSE: LLY) made some important disclosures on Wednesday morning regarding a pair of coronavirus treatment candidates and their potential path to accessibility in a hospital near you. In a nutshell, new clinical trial data for LY-CoV555 and LY-CoV016 suggest the pair of antibodies go a long way toward improving outcomes for COVID-19 patients.
Image source: Getty Images.
Based on a recent interim analysis, the company has submitted an initial request to the FDA for an emergency use authorization (EUA) that would allow physicians to administer LY-CoV555 to higher-risk patients diagnosed with mild-to-moderate COVID-19. The amount of SARS-CoV-2 circulating in the bloodstreams of patients treated with LY-CoV555 as a monotherapy fell significantly compared to those given a placebo, and it looks like combining LY-CoV555 with LY-CoV016 is even more effective.
Source Fool.com
